Profusa Files Prospectus Supplement for Resale of 7.17M Shares, Enabling Massive Dilution Post-Split

summarizeSummary

Profusa filed a prospectus supplement enabling the resale of 7.17 million shares by existing holders, representing over 1300% dilution post-reverse split, and disclosed an equity line of credit for up to $100 million, significantly exceeding its market cap.

check_boxKey Events · Financing and Capital Events · PFSA

• Massive Potential Dilution

  Selling stockholders are enabled to resell 7,170,891 shares of common stock, which represents over 1300% of the company's approximately 530,000 post-split outstanding shares.

• Equity Line of Credit (ELOC) Program

  The company may sell up to $100,000,000 in shares to Ascent Partners Fund LLC under an existing ELOC agreement, an amount that is approximately 188 times its current market capitalization.

• Reverse Stock Split Confirmed

  The filing incorporates an 8-K confirming a 1-for-25 reverse stock split effective July 7, 2026, which adjusted all share numbers in the prospectus.

• No Direct Proceeds from Resale

  The company will not receive any proceeds from the sale of the 7.17 million shares by the selling stockholders.

auto_awesomeAnalysis · PFSA · Industrial Applications And Services

This filing updates the prospectus for the resale of 7.17 million shares by selling stockholders, which represents over 1300% of the company's current outstanding shares following a 1-for-25 reverse stock split. While the company itself will not receive proceeds from these specific resales, the filing also details an equity line of credit (ELOC) that could allow the company to sell up to $100 million in shares, an amount vastly exceeding its current market capitalization. This continues a pattern of highly dilutive financing for a company facing severe financial distress and Nasdaq delisting threats.